Skip to main content
OpenTrials
Completed

NCT Number: NCT02623556

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

720 cases TB (Tuberculosis patients) participants、360 cases non-TB participants with lung disease and suspected TB patients who all meet the standard are divided into different groups through a randomized and blind method. Every subject inject intradermally ESAT6-CFP10 and TB-PPD (tuberculin purified protein derivative) in different arms of the same person by blind method. Specific gama-interferon (γ-IFN) detection is needed before the injection.Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h. At the same time, we observe all kind of adverse events.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Wuxi NO.5 People's Hospital, Wuxi, Jiangsu, China

Loading trial locations.

About this study

Firstly, 720 cases TB (Tuberculosis) participants who meet the standard respectively are divided into different groups through a randomized and blind method.

  • ESAT6-CFP10(10ug/ml) in left arm
  • ESAT6-CFP10(10ug/ml) in right arm. Inject intradermally ESAT6-CFP10 and TB-PPD in different arms of the same participant. For each of participant, the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h. At the same time, we observe the vital signs (breathing, heart rate, blood pressure and temperature), local reactions (rash, pain, itching and skin mucous membrane) and a variety of adverse events.

Secondly, 360 cases non-TB participants with lung disease and suspected TB participants are divided into two different groups and the procedure are as the same as 720 cases TB.

Thirdly,suspected TB participants are put under TB (Tuberculosis patients) or non-TB participants with lung disease by diagnosis when out group.

Finally, we calculate the sensitivity (positive coincidence rate) by TB (Tuberculosis patients), the specificity (negative coincidence rate) by non-TB participants with lung disease, and verify the safety and effectiveness of ESAT6-CFP10(10ug/ml) for the clinical auxiliary diagnosis of tuberculosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

of TB (tuberculosis:include pulmonary tuberculosis and extra pulmonary tuberculosis) subjects:

  • judge the pulmonary tuberculosis patient according to Health industry standard of the People's Republic of China WS288-2008:Diagnostic Criteria for pulmonary tuberculosis;
  • 18 to 65 years old ,no gender limited;
  • Consent and signed informed consent forms (ICF);
  • Comply with follow-up.

Inclusion criteria

of extra pulmonary tuberculosis subjects:

  • Diagnosed extra pulmonary tuberculosis by epidemiology, imaging, clinical symptoms, pathological examination and so on;
  • Lesions outside the lungs;
  • be in unfinished reinforced phase by chemotherapy;

Exclusion criteria

of TB (tuberculosis) subjects:

  • Accompanied by the following severe illness:advanced cancer, diabetes, copd in acute episodes, acute/progressive liver disease or kidney disease, congestive heart failure, ect;
  • Taking part in other clinical or within three months involved in any other clinical;
  • Severe allergic constitution:allergic to two or more drugs;
  • in pregnancy or lactation;
  • in a mental illness;
  • Any conditions affect the trial evaluation by investigator's judgement.

Inclusion criteria

of non-TB participants with lung disease:

  • A clear lung disease but can exclude pulmonary tuberculosis by clinical symptoms, imaging, laboratory examination.
  • 18 to 65 years old, no gender limited;
  • Consent and signed informed consent forms (ICF);
  • Comply with follow-up.

Exclusion criteria

of non-TB participants with lung disease:

  • Accompanied by the following severe illness: advanced cancer, diabetes, copd in acute episodes, acute/progressive liver disease or kidney disease, congestive heart failure, ect;
  • Taking part in other clinical or within three months involved in any other clinical;
  • Severe allergic constitution: allergic to two or more drugs;
  • in pregnancy or lactation;
  • in a mental illness;
  • history of tuberculosis;
  • Any conditions affect the trial evaluation by investigator's judgement.

Inclusion criteria

of suspected TB participants with lung disease:

  • Cases who have pulmonary tuberculosis by clinical symptoms/signs:appear cough、cough with hemoptysis、pectoralgia、dyspnea、fever(low-grade fever at afternoon),together with night sweats、weak、loss of appetite、weight loss,and so on,or other easily-confused respiratory system disease with TB;
  • 18 to 65 years old, no gender limited;
  • Consent and signed informed consent forms (ICF);
  • Comply with follow-up.

Exclusion criteria

of suspected TB participants with lung disease:

  • Accompanied by the following severe illness: advanced cancer, diabetes, copd in acute episodes, acute/progressive liver disease or kidney disease, congestive heart failure, ect;
  • Taking part in other clinical or within three months involved in any other clinical;
  • Severe allergic constitution: allergic to two or more drugs;
  • in pregnancy or lactation;
  • in a mental illness;
  • history of tuberculosis;
  • Any conditions affect the trial evaluation by investigator's judgement.

Treatment and study plan

ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm

Biological

All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.

ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm

Biological

All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.

Primary outcomes

  1. Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patients

    Time frame: within 72h after injection

    We measure the size of induration or redness at 24h, 48h, 72h after administered intradermally left arm (random injected ESAT6-CFP10 or PPD)

  2. Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patients

    Time frame: within 72h after injection

    We measure the size of induration or redness at 24h, 48h, 72h after administered intradermally right arm (random injected ESAT6-CFP10 or PPD)

  3. Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung disease

    Time frame: within 72h after injection

    We measure the size of induration or redness at 24h, 48h, 72h after administered intradermally left arm (random injected ESAT6-CFP10 or PPD)

  4. Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung disease

    Time frame: within 72h after injection

    We measure the size of induration or redness at 24h, 48h, 72h after administered intradermally right arm (random injected ESAT6-CFP10 or PPD)

Secondary outcomes

  1. Number of participants with Adverse Events

    Time frame: within 72h after injection two drug each participant

Sponsors and collaborators

Lead sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Industry

Collaborators

  • Air Force Military Medical University, China
  • Anhui Provincial Hospital
  • Beijing Chest Hospital
  • First Affiliated Hospital of Chongqing Medical University
  • Fuzhou Pulmonary Hospital of Fujian
  • Proswell Medical Corporation
  • Shanghai Public Health Clinical Center
  • Shenzhen Third People's Hospital
  • Tianjin Haihe Hospital
  • Wuhan Institute for Tuberculosis Control
  • Wuxi Hospital for Infectious Diseases
  • Zhenjiang Third People's Hospital

Registry information

Official study title

For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6 - CFP10 Dose of Certain Phase III Clinical Research

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Dec 7, 2015
Registry last updated
Apr 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.